- Home
- LSTA vs INKT Comparison
LSTA vs INKT Comparison
Compare LSTA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- INKT
- Stock Information
- Founded
- LSTA 1980
- INKT 2017
- Country
- LSTA United States
- INKT United States
- Employees
- LSTA N/A
- INKT N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- LSTA Health Care
- INKT Health Care
- Exchange
- LSTA Nasdaq
- INKT Nasdaq
- Market Cap
- LSTA 24.1M
- INKT 28.9M
- IPO Year
- LSTA N/A
- INKT 2021
- Fundamental
- Price
- LSTA $2.61
- INKT $7.04
- Analyst Decision
- LSTA Strong Buy
- INKT Strong Buy
- Analyst Count
- LSTA 1
- INKT 2
- Target Price
- LSTA $15.00
- INKT $37.50
- AVG Volume (30 Days)
- LSTA 15.8K
- INKT 14.7K
- Earning Date
- LSTA 08-11-2025
- INKT 08-12-2025
- Dividend Yield
- LSTA N/A
- INKT N/A
- EPS Growth
- LSTA N/A
- INKT N/A
- EPS
- LSTA N/A
- INKT N/A
- Revenue
- LSTA $1,000,000.00
- INKT N/A
- Revenue This Year
- LSTA N/A
- INKT N/A
- Revenue Next Year
- LSTA N/A
- INKT N/A
- P/E Ratio
- LSTA N/A
- INKT N/A
- Revenue Growth
- LSTA N/A
- INKT N/A
- 52 Week Low
- LSTA $1.87
- INKT $4.56
- 52 Week High
- LSTA $4.20
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- LSTA 50.61
- INKT 47.56
- Support Level
- LSTA $2.36
- INKT $6.91
- Resistance Level
- LSTA $3.07
- INKT $7.51
- Average True Range (ATR)
- LSTA 0.23
- INKT 0.32
- MACD
- LSTA 0.02
- INKT -0.02
- Stochastic Oscillator
- LSTA 37.50
- INKT 27.28
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.